Table 4 Antifibrotic use

Sample size, n (%)

781 (43.4)

202 (11.2)

190 (10.6)

255 (14.2)

370 (20.6)

1,798 (100.0)

Any nintedanib discontinuation (yes/no), mean (sd)

0.6% (8.0%)

37.6% (48.6%)

55.3% (49.9%)

98.0% (13.9%)

100.0% (0.0%)

44.8% (49.7%)

< 0.001

Any pirfenidone use (yes/no), mean (sd)

0.9% (9.4%)

1.5% (12.1%)

14.7% (35.5%)

22.4% (41.7%)

18.6% (39.0%)

9.1% (28.8%)

< 0.001

Any pirfenidone use conditional on nintedanib discontinuation (yes/no), mean (sd)

0.0% (0.0%)

1.3% (11.5%)

21.9% (41.6%)

22.8% (42.0%)

18.6% (39.0%)

18.6% (38.9%)

< 0.001

PDC

 Nintedanib, mean (sd)

0.961 (0.043)

0.712 (0.145)

0.738 (0.112)

0.364 (0.103)

0.127 (0.055)

0.653 (0.343)

< 0.001

 Pirfenidone, mean (sd)

0.000 (0.005)

0.001 (0.008)

0.012 (0.032)

0.025 (0.056)

0.024 (0.063)

0.010 (0.039)

< 0.001

 Nintedanib + pirfenidone, mean (sd)

0.961 (0.043)

0.713 (0.145)

0.750 (0.112)

0.389 (0.116)

0.151 (0.085)

0.663 (0.335)

< 0.001